Oxycodone referred for PBAC decision

Regulators will consider the PBS listing of non-tamper proof oxycodone formulations, the pending availability of which is generating concern in pharmacy.

Following the expiry of the oxycodone patent in July, the Federal Government has approved a generic, non-tamperproof formulation.

However, Mundipharma, manufacturer of the originator product, Oxycontin, have sponsored a submission to the Pharmaceutical Benefits Advisory Committee (PBAC), calling for restrictions to the